Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.
Richez B, Cantarel C, Durrieu F, Soubeyran I, Blanchi J, Pernot S, Chakiba Brugère C, Roubaud G, Cousin S, Etienne G, Floquet A, Babre F, Rivalan J, Lalet C, Narbonne M, Belaroussi Y, Bellera C, Mathoulin-Pélissier S. Richez B, et al. Among authors: cantarel c. Int J Environ Res Public Health. 2023 May 25;20(11):5949. doi: 10.3390/ijerph20115949. Int J Environ Res Public Health. 2023. PMID: 37297553 Free PMC article.
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
Cousin S, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, Pernot S, Bellera C, Kind M, Auzanneau C, Le Loarer F, Soubeyran I, Bessede A, Italiano A. Cousin S, et al. Among authors: cantarel c. Clin Cancer Res. 2021 Apr 15;27(8):2139-2147. doi: 10.1158/1078-0432.CCR-20-3416. Epub 2021 Jan 25. Clin Cancer Res. 2021. PMID: 33495314 Clinical Trial.
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Cousin S, et al. Among authors: cantarel c. Eur J Cancer. 2022 Feb;162:161-169. doi: 10.1016/j.ejca.2021.11.012. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998048 Clinical Trial.
Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison.
Penel N, Cantarel C, Chemin-Airiau C, Ducimetiere F, Gouin F, Le Loarer F, Toulmonde M, Piperno-Neumann S, Bellera C, Honore C, Blay JY, Mathoulin-Pelissier S. Penel N, et al. Among authors: cantarel c. Ther Adv Med Oncol. 2023 Aug 31;15:17588359231192400. doi: 10.1177/17588359231192400. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37661954 Free PMC article.
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, Guegan JP, Rey C, Sautès-Fridman C, Bougoüin A, Cantarel C, Kind M, Spalato M, Dadone-Montaudie B, Le Loarer F, Blay JY, Fridman WH. Italiano A, et al. Among authors: cantarel c. Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26. Nat Med. 2022. PMID: 35618839 Clinical Trial.
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M, Guegan JP, Spalato-Ceruso M, Peyraud F, Kind M, Vanhersecke L, Le Loarer F, Perret R, Cantarel C, Bellera C, Bessede A, Italiano A. Toulmonde M, et al. Among authors: cantarel c. Mol Cancer. 2024 Feb 20;23(1):38. doi: 10.1186/s12943-024-01946-8. Mol Cancer. 2024. PMID: 38378555 Free PMC article. Clinical Trial.
11 results